180 related articles for article (PubMed ID: 38130463)
1. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
Yang L; Jing Y; Xia X; Yin X
J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
[TBL] [Abstract][Full Text] [Related]
2. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
Front Oncol; 2021; 11():753119. PubMed ID: 34733788
[TBL] [Abstract][Full Text] [Related]
3. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
4. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
Lu Q; Ding X; Huang T; Zhang S; Li Y; Xu L; Chen G; Ying Y; Wang Y; Feng Z; Wang L; Zou X
Am J Transl Res; 2019; 11(9):5728-5739. PubMed ID: 31632543
[TBL] [Abstract][Full Text] [Related]
5. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
He L; Chen C; Gao G; Xu K; Ma Z
Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
[TBL] [Abstract][Full Text] [Related]
6. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
7. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
8. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.
Vartak R; Saraswat A; Yang Y; Chen ZS; Patel K
Pharm Res; 2022 Nov; 39(11):2745-2759. PubMed ID: 35146591
[TBL] [Abstract][Full Text] [Related]
10. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
11. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
12. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
13. miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.
Tonouchi E; Gen Y; Muramatsu T; Hiramoto H; Tanimoto K; Inoue J; Inazawa J
Sci Rep; 2018 Mar; 8(1):4482. PubMed ID: 29540837
[TBL] [Abstract][Full Text] [Related]
14. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
17. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
He Y; Ju Y; Hu Y; Wang B; Che S; Jian Y; Zhuo W; Fu X; Cheng Y; Zheng S; Huang N; Qian Z; Liu J; Zhou P; Gao X
J Control Release; 2023 Feb; 354():155-166. PubMed ID: 36538950
[TBL] [Abstract][Full Text] [Related]
18. Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.
Kim YH; Kim M; Kim JE; Yoo M; Lee HK; Lee CO; Yoo M; Jung KY; Kim Y; Choi SU; Park CH
Oncol Lett; 2021 Jun; 21(6):473. PubMed ID: 33907583
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
